Whole-sporozoite malaria vaccines: where we are, where we are going
Abstract The malaria vaccination landscape has seen significant advancements with the recent endorsement of RTS,S/AS01 and R21/Matrix-M vaccines, which target the pre-erythrocytic stages of Plasmodium falciparum (Pf) infection. However, several challenges remain to be addressed, including the incomp...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2024-09-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s44321-024-00131-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850181989251940352 |
|---|---|
| author | Diana Moita Miguel Prudêncio |
| author_facet | Diana Moita Miguel Prudêncio |
| author_sort | Diana Moita |
| collection | DOAJ |
| description | Abstract The malaria vaccination landscape has seen significant advancements with the recent endorsement of RTS,S/AS01 and R21/Matrix-M vaccines, which target the pre-erythrocytic stages of Plasmodium falciparum (Pf) infection. However, several challenges remain to be addressed, including the incomplete protection afforded by these vaccines, their dependence on a single Pf antigen, and the fact that they were not designed to protect against P. vivax (Pv) malaria. Injectable formulations of whole-sporozoite (WSpz) malaria vaccines offer a promising alternative to existing subunit vaccines, with recent developments including genetically engineered parasites and optimized administration regimens. Clinical evaluations demonstrate varying efficacy, influenced by factors, such as immune status, prior exposure to malaria, and age. Despite significant progress, a few hurdles persist in vaccine production, deployment, and efficacy in malaria-endemic regions, particularly in children. Concurrently, transgenic parasites expressing Pv antigens emerge as potential solutions for PvWSpz vaccine development. Ongoing clinical studies and advancements in vaccine technology, including the recently described PfSPZ-LARC2 candidate, signify a hopeful future for WSpz malaria vaccines, which hold great promise in the global fight against malaria. |
| format | Article |
| id | doaj-art-833ea4592cbc47068f6e3cfa5afd0372 |
| institution | OA Journals |
| issn | 1757-4684 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-833ea4592cbc47068f6e3cfa5afd03722025-08-20T02:17:46ZengSpringer NatureEMBO Molecular Medicine1757-46842024-09-0116102279228910.1038/s44321-024-00131-0Whole-sporozoite malaria vaccines: where we are, where we are goingDiana Moita0Miguel Prudêncio1Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de LisboaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de LisboaAbstract The malaria vaccination landscape has seen significant advancements with the recent endorsement of RTS,S/AS01 and R21/Matrix-M vaccines, which target the pre-erythrocytic stages of Plasmodium falciparum (Pf) infection. However, several challenges remain to be addressed, including the incomplete protection afforded by these vaccines, their dependence on a single Pf antigen, and the fact that they were not designed to protect against P. vivax (Pv) malaria. Injectable formulations of whole-sporozoite (WSpz) malaria vaccines offer a promising alternative to existing subunit vaccines, with recent developments including genetically engineered parasites and optimized administration regimens. Clinical evaluations demonstrate varying efficacy, influenced by factors, such as immune status, prior exposure to malaria, and age. Despite significant progress, a few hurdles persist in vaccine production, deployment, and efficacy in malaria-endemic regions, particularly in children. Concurrently, transgenic parasites expressing Pv antigens emerge as potential solutions for PvWSpz vaccine development. Ongoing clinical studies and advancements in vaccine technology, including the recently described PfSPZ-LARC2 candidate, signify a hopeful future for WSpz malaria vaccines, which hold great promise in the global fight against malaria.https://doi.org/10.1038/s44321-024-00131-0Plasmodium falciparumPlasmodium vivaxClinical EvaluationPfSPZVaccination Regimens |
| spellingShingle | Diana Moita Miguel Prudêncio Whole-sporozoite malaria vaccines: where we are, where we are going EMBO Molecular Medicine Plasmodium falciparum Plasmodium vivax Clinical Evaluation PfSPZ Vaccination Regimens |
| title | Whole-sporozoite malaria vaccines: where we are, where we are going |
| title_full | Whole-sporozoite malaria vaccines: where we are, where we are going |
| title_fullStr | Whole-sporozoite malaria vaccines: where we are, where we are going |
| title_full_unstemmed | Whole-sporozoite malaria vaccines: where we are, where we are going |
| title_short | Whole-sporozoite malaria vaccines: where we are, where we are going |
| title_sort | whole sporozoite malaria vaccines where we are where we are going |
| topic | Plasmodium falciparum Plasmodium vivax Clinical Evaluation PfSPZ Vaccination Regimens |
| url | https://doi.org/10.1038/s44321-024-00131-0 |
| work_keys_str_mv | AT dianamoita wholesporozoitemalariavaccineswherewearewherewearegoing AT miguelprudencio wholesporozoitemalariavaccineswherewearewherewearegoing |